Clinical Trial Update: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegylated interferon alfa-2a plus tenofovir versus tenofovir alone in chronic hepatitis B has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Tenofovir (Tenofovir)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED | Results posted: 2022-10-12